An update from HUTCHMED (China) ( ($HK:0013) ) is now available. HUTCHMED announced significant results from the FRUSICA-2 registration trial, ...

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of ...

A new study shows that kidney cancer rates in Merrimack are about 38% higher than expected and points to another possible ...

Xencor (NASDAQ:XNCR) shares lost ~13% on Tuesday as the company refuted concerns over an upcoming data readout from an early-stage trial for its kidney cancer drug, XmAb819, scheduled to be presented ...

If approved in RCC, fruquintinib will be available for three indications, including endometrial and colorectal cancer.

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 13, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; ...

Discover the most anticipated abstracts on renal cell carcinoma and bladder cancer at the 2025 ESMO Congress in Berlin. With the 2025 European Society of Medical Oncology (ESMO) Congress starting on ...

A diagnosis of kidney cancer, also known as renal cancer, requires strong partnership with your oncologist. This overview is ...

Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the presentation of ...

Samer A. Srour, MB ChB, MS, has long hoped the remarkable success of chimeric antigen receptor therapy for treatment of hematologic malignancies could be replicated in other cancer types.“There is a ...

The incidence of renal cell carcinoma among the included patients with Fabry disease was 15 times higher than in the general population. Patients with Fabry disease appear to have a higher incidence ...

Medical artificial intelligence (AI) company Lunit announced on October 13 that it will present three studies on predicting immunotherapy response ...